Examples like Cursor, reaching $100M ARR with under 20 employees, signal a new paradigm of hyper-efficient company building. This is driven by AI-enabled workflows and small, highly leveraged teams, challenging traditional venture-backed scaling models.

Uniquity Bio, a 35-person firm, runs three Phase 2 trials concurrently—a resource-intensive strategy. This is possible because substantial private funding (from Blackstone) allows them to focus on clinical advancement rather than constant fundraising, de-risking an aggressive, multi-pronged approach.

Contradicting the common startup goal of scaling headcount, the founders now actively question how small they can keep their team. They see a direct link between adding people, increasing process, and slowing down, leveraging a small, elite team as a core part of their high-velocity strategy.

Actuate Therapeutics maintains high capital efficiency by keeping its full-time headcount low. The company is built around a trusted core team and supplemented by an extensive stable of "best of breed" consultants who are engaged on an as-needed basis, minimizing overhead costs.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

Iolyx Therapeutics' CEO notes the surprising capital efficiency of lean biotech. Her team advanced a drug from discovery through Phase 2 for approximately $20 million—an amount she could have easily spent on a single marketing campaign at Genentech. This highlights the operational leverage of focused, small teams.

Linear's COO argues that team size doesn't dictate business impact. By keeping its team intentionally lean (around 140 people for 25k+ customers), the company maintains a high talent bar and focuses on metrics like revenue and growth over headcount.

Ona Therapeutics maintains a small team by following a simple rule: outsource functions that external experts can do better (like CROs and manufacturing) at a reasonable price. This allows them to focus all internal resources on their core, specialized competency of designing novel molecules and advancing their pipeline.

Partners can use Lila's integrated AI and lab platform to run entire R&D programs, functioning as a 'zero-FTE startup.' This allows a small team with a scientific idea to achieve in months what a traditional biotech takes years and millions to accomplish, dramatically lowering the barrier to entry.